DTB Podcast (BMJ Group)

In this podcast recorded in early November, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the December issue of DTB. They provide an overview of the editorial that discusses the need to record the sex and gender of all participants in clinical trials and the importance of recognising diversity and inclusivity in clinical research - https://dtb.bmj.com/content/62/12/178. They talk about a commentary article that addresses claims made in a systematic review that menopausal HT may support neurological function and reduce the risk of Alzeheimer's disease - https://dtb.bmj.com/content/62/12/179. The main article provides an overview of daridorexant for the management of chronic sleep - https://dtb.bmj.com/content/62/12/183. They begin by providing an update on the NICE guidance for tirzepatide and highlighting the publication of a toolkit for repeat prescribing in general practice.   Other related links NICE guidance on tirzepatide: https://www.nice.org.uk/guidance/gid-ta11156/documents/html-content-10 Repeat prescribing toolkit: https://www.rpharms.com/resources/repeat-prescribing-toolkit

In this podcast recorded in early January, David Phizackerley provides a brief overview of the February 2025 issue of DTB. The editorial discusses the importance of shared decision making and calls on guideline developers to produce patient decision aids to accompany their guidance - https://dtb.bmj.com/content/63/2/18. A DTB Select item summarises a study that evaluated implementation of NHS England’s type 2 diabetes path to remission programme -  https://dtb.bmj.com/content/63/2/19. The authors of a DTB Commentary article review a UK primary care study which reported that treatment with antihypertensive medicines in older people with complex health needs was associated with an increased risk of acute kidney injury (AKI) and a short-term increased risk of falls - https://dtb.bmj.com/content/63/2/20. The main article explores the evidence for gefapixant in the treatment of refractory or unexplained chronic cough in adults - https://dtb.bmj.com/content/63/2/22.   Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the August 2023 issue of DTB. They discuss measurement of fractional exhaled nitric oxide (FeNO) in the management of asthma (https://dtb.bmj.com/content/61/8/114). They review a study that assessed the use of H. pylori eradication in people taking low-dose aspirin (https://dtb.bmj.com/content/61/8/116). The main article explores the evidence for the use of finerenone for CKD associated with type 2 diabetes (https://dtb.bmj.com/content/61/8/120).

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email dtb@bmj.com. Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the October 2023 issue of DTB. They discuss NHS prescription charges in England and the impact they have on people with long-term ill health (https://dtb.bmj.com/content/61/10/146). They talk about a study that assessed the incidence of retinopathy associated with hydroxychloroquine (https://dtb.bmj.com/content/61/10/148). The main article discusses intravenous vitamins and reviews the evidence for their use for serious medical conditions and the evidence for their use in the absence of a specific vitamin deficiency or medical condition (https://dtb.bmj.com/content/61/10/151).    The latest issue of Australian Prescriber mentioned in thia podcast is available from https://australianprescriber.tg.org.au/.   Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email dtb@bmj.com. Thank you for listening.

In this podcast recorded in early August, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the September issue of DTB. They discuss the editorial (https://dtb.bmj.com/content/62/9/130) that highlights some of the challenges associated with NHS England's national medicines optimisation measures for Integrated Care Boards. They talk about the MHRA's recent safety alert on the risk of an interaction between tramadol and warfarin (https://dtb.bmj.com/content/62/9/131), which was prompted by a coroner's prevention of future deaths report (summarised in a DTB article in March https://dtb.bmj.com/content/62/3/36). The main article reviews the evidence for icosapent ethyl for cardiovascular risk reduction (https://dtb.bmj.com/content/62/9/135).

 

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.

In a series of podcasts to mark the 60th anniversary of DTB, we talk to some of DTB's Editorial Board members and other colleagues about their work and their involvement with DTB. In this podcast, David Phizackerley (DTB deputy editor) talks to Barbara Mintzes (DTB associate editor)  who is Associate Professor at the School of Pharmacy and Charles Perkins Centre at the University of Sydney, where she has worked since 2015.  Her background is in epidemiology and the main focus of her work is on pharmaceutical policy, including the effects of direct-to-consumer advertising and physician-directed promotion on medicine use. Barbara talks about her interest in medicines policies, the impact of pharmaceutical and medical device company payments to clinicians, medicalisation of normal life, medicine safety scandals and the impact on those who have been harmed by medicines with a particular focus on women's health.   Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email dtb@bmj.com. Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the September 2023 issue of DTB. They discuss concerns over redacted data in NICE appraisal documents (https://dtb.bmj.com/content/61/9/130). They review a placebo-controlled study that assessed the use of spironolactone for women with acne (https://dtb.bmj.com/content/61/9/132). The main article explores anticholinergic burden and the risk of cognitive decline, dementia and increased mortality associated with long-term use of drugs with anticholinergic activity (https://dtb.bmj.com/content/61/9/135).

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email dtb@bmj.com. Thank you for listening.

In this podcast recorded in early February, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the March 2024 issue of DTB. They discuss the editorial highlighting the important work that the founders of The Medical Letter, Worst Pills, Best Pills and Drug and Therapeutics Bulletin did to scrutinise the safety of medicines and the need to challenge the processes by which medicines are licensed, appraised, commissioned and promoted (https://dtb.bmj.com/content/62/3/34). They review a coroner's Prevention of Future Deaths report that highlighted an interaction between tramadol and warfarin (https://dtb.bmj.com/content/62/3/36). They also talk about a study that compared the emergency contraceptive efficacy of levonorgestrel plus piroxicam with levonorgestrel plus placebo (https://dtb.bmj.com/content/62/3/38). The main article considers the effectiveness of low or very low calorie diets in achieving remission of type 2 diabetes (https://dtb.bmj.com/content/62/3/39).   Link Mathew R. Prescribing isn’t a single act—getting it right requires time and effort. BMJ 2024;384:q279 (https://www.bmj.com/content/384/bmj.q279) Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email dtb@bmj.com. Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the July 2023 issue of DTB. They discuss evidence-based medicine, access to evidence and increasing use of press releases and social media to present evidence (https://dtb.bmj.com/content/61/7/98). They talk about the safety of isotretinoin (https://dtb.bmj.com/content/61/7/99) and review a study that assessed the accuracy of conflict of interest statements in clinical guidelines (https://dtb.bmj.com/content/61/7/100). The main review article explores the evidence for cardiac and renal effects of SGLT2 inhibitors (https://dtb.bmj.com/content/61/7/103). They begin by discussing the impact of the shortage of Utrogestan.

In this podcast recorded in early September, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the October issue of DTB. They discuss the editorial that highlights the work of the Common Sense in Oncology movement and its aim "to counteract the trend towards irrational, industry-designed, profit-driven cancer drug development" - https://dtb.bmj.com/content/62/10/146. They talk about the results of a systematic review and meta-analysis of two randomised controlled trials that assessed the effect of treating people who have device-detected subclinical atrial fibrillation (AF) with a direct oral anticoagulant - https://dtb.bmj.com/content/62/10/147. The main article discusses the management of hypertension in older people - https://dtb.bmj.com/content/62/10/149. They begin by highlighting an article* that considers the challenges associated with the introduction of new drugs for the treatment of Alzheimer's disease.

*Walsh S, Merrick R, Milne R, et al. Considering challenges for the new Alzheimer's drugs: clinical, population, and health system perspectives. Alzheimers Dement. 2024. doi: 10.1002/alz.14108. [Epub ahead of print 4 Aug 2024]. https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14108

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.

In this podcast recorded in early June, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) ignore the UK general election, the T20 cricket world cup and the European football championship and talk about the July 2024 issue of DTB. They discuss the editorial that highlights trial data showing that dupilumab had a modest effect on reducing COPD exacerbations, and question whether more drugs or greater investment in pulmonary rehabilitation and smoking cessation services are a better use of resources. They review a coroner's prevention of future deaths report that highlights the need to raise awareness of the dangers of propranolol overdose. The main article discusses the management of exacerbations of COPD in primary care.  

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.

 

In this podcast recorded in early May, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the June 2024 issue of DTB. They discuss the editorial that highlights changes to the use of gonadal and fetal shielding for diagnostic imaging (see link). They review the results of a study that assessed the benefit of antibiotics for treating acute sinusitis in children aged 2-11 years.  The main article considers the evidence for ritlecitinib, a Janus kinase enzyme inhibitor that is licensed for the treatment of severe alopecia areata in adults and adolescents aged ≥12 years. They begin the podcast by discussing newspaper headlines generated by an international conference on obesity. Link https://www.bir.org.uk/education-and-events/patient-shielding-guidance.aspx Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email dtb@bmj.com. Thank you for listening.

In this podcast recorded in early January, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the February 2024 issue of DTB. They discuss the editorial that highlights problems associated with shortages of ADHD medicines.  They talk about two safety alerts issued by the Medicines and Healthcare products Regulatory Agency that focus on the adverse effects of fluoroquinolone antibiotics on physical and mental health.  The main article considers various NHS initiatives that have attempted to limit primary care prescribing of drugs that are deemed to have limited clinical value. They begin the podcast with sad news of the death of Dr Sidney Wolfe (1937-2024), a colleague and friend who co-founded the US Health Research Group and Public Citizen (a nonprofit consumer advocacy organisation) and who was "a towering public health leader and an unparalleled consumer champion".    Links

• Remembering Sid Wolfe: https://www.citizen.org/remembering-sidney-wolfe/
• Mandatory disclosure of all pharmaceutical and medical device companies’ payments to healthcare providers: learning from the US: https://dtb.bmj.com/content/60/4/52
• Worst Pills, Best Pills: https://www.citizen.org/topic/safe-affordable-drugs-devices/worst-pills-best-pills/

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email dtb@bmj.com. Thank you for listening.

In this podcast recorded in early February, David Phizackerley and Julian Treadwell (DTB Associate Editor) provide an overview of the March 2025 issue of DTB. Julian talks about his work as an academic GP based at Bristol University. He explains why and how he developed the GP Evidence website (https://gpevidence.org/) as a resource for health professionals to use as part of a shared decision making process, and talks about the importance of providing patients with information on the absolute benefits and harms of different treatment options for long-term conditions.   The editorial discusses a paper published in The Lancet on the population-health impact of new drugs recommended by NICE and highlights the tension between NICE's role in ensuring that treatments are a cost-effective use of taxpayers’ money and its role in championing the for-profit life-sciences - https://dtb.bmj.com/content/63/3/34. A DTB Select item summarises safety alerts issued by the US Food and Drug Administration and the European Medicines Agency on liver problems associated with fezolinetant (▼Veoza), a drug licensed for the treatment of moderate-to-severe vasomotor symptoms associated with the menopause - https://dtb.bmj.com/content/63/3/36. The main article provides an overview of systemic anticancer treatments and conventional cytotoxic drugs - https://dtb.bmj.com/content/63/3/37.   Links GP Evidence (https://gpevidence.org/)   Naci H, Murphy P, Woods B, et al. Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis. The Lancet 2025;405:50–60. (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02352-3/fulltext)    Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.

In this podcast recorded in early March, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the April 2024 issue of DTB. They discuss the editorial that questions whether drug safety alerts are effective in changing practice and whether more needs to be done to implement safety recommendations (https://dtb.bmj.com/content/62/4/50). They review the Medicines and Healthcare products Regulatory Agency's latest risk minimisation measures for using valproate, which include a guide for healthcare professionals, a guide for patients, an annual risk acknowledgement form and an information card for patients (https://dtb.bmj.com/content/62/4/53). The main article considers the evidence for a new progestogen only pill containing drospirenone (https://dtb.bmj.com/content/62/4/55). They begin by discussing recent concerns over neuropsychiatric reactions associated with montelukast. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email dtb@bmj.com. Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the June 2023 issue of DTB. They discuss new guidelines on post-exposure prophylaxis for varicella or shingles during pregnancy (https://dtb.bmj.com/content/61/6/82). They review the effect of low-dose aspirin on fractures and falls (https://dtb.bmj.com/content/61/6/85), and talk about a study that does not provide meaningful cardiovascular outcome data for inclisiran (https://dtb.bmj.com/content/61/6/86). The main review article explores hospitalisation as a consequence of medication-related harm and the need to reduce the burden of harm caused by medication (https://dtb.bmj.com/content/61/6/87). They begin by discussing an announcement from NHS England that antibiotics will be provided without the need for a prescription from community pharmacies to free up GP time.

The contact address for the DTB team is dtb@bmj.com. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the December 2023 issue of DTB. They discuss monitoring drugs in primary care and the need to rationalise the number of blood tests undertaken (https://dtb.bmj.com/content/61/12/178). They talk about a study that reported the effect of bempedoic acid on a composite cardiovascular outcome (https://dtb.bmj.com/content/61/12/180). The main article is a review of semaglutide as an option for weight management and discusses the evidence for its use and some of the hype that has surrounded the its launch (https://dtb.bmj.com/content/61/12/182). They begin by responding to a listener's complaint about terminology.   Related link: Aronson JK. When I use a word . . . Medicines regulation—apothecaries, quacks, chemists, druggists, pharmacists. BMJ 2023;383:p2603. https://www.bmj.com/content/383/bmj.p2603    Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email dtb@bmj.com. Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the November 2023 issue of DTB. They discuss the history of the BNF and the announcement that the 86th edition of the BNF and the 2023–2024 edition of the BNF for Children will be the last print issues to be purchased by the National Institute for Health and Care Excellence for the NHS in England (https://dtb.bmj.com/content/61/11/162 and https://dtb.bmj.com/content/61/11/166). They talk about a retrospective review of a case series of UK coroners’ Reports to Prevent Future Deaths that found that around one in five reports involved a medicine (https://dtb.bmj.com/content/61/11/165). The main article provides an introduction to pharmacogenetics (https://dtb.bmj.com/content/61/11/168). They begin by responding to a listener's email.   Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email dtb@bmj.com. Thank you for listening.

In this podcast recorded in early March, David Phizackerley (DTB Editor-in-Chief) and James Cave (DTB Editor-in-Chief Emeritus) provide an overview of the April 2025 issue of DTB. The editorial discusses concerns over the use of feminist empowerment messages to sell tests and treatments - https://dtb.bmj.com/content/63/4/50. A DTB Select item summarises the results of an observational study that assessed the association between initiation of a triptan and the risk of myocardial infarction or stroke - https://dtb.bmj.com/content/63/4/51. The main article provides an overview of initiating angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonists in adults with CKD, highlighting current guideline recommendations and providing a practical approach to dealing with the challenges associated with their use - https://dtb.bmj.com/content/63/4/54.   Links Health Innovation Network: https://thehealthinnovationnetwork.co.uk/news/launch-of-new-game-changing-guide-to-tackle-overprescribing-and-support-governments-shifts-to-prevention-and-community/    Tackling overprescribing report: https://thehealthinnovationnetwork.co.uk//wp-content/uploads/2025/02/Health-Innovation-Network-Polypharmacy-Guide-Feb-2025.pdf    GP Evidence: (https://gpevidence.org/)   Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.

In this podcast recorded in early October, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the November issue of DTB. They provide an overview of the editorial that discusses the need to support people taking drugs to help with weight loss: "Providing the drug is only one part of the process and if the other elements are not available to support people with obesity the full benefits of these expensive treatments will not be realised" - https://dtb.bmj.com/content/62/11/162. They talk about the results of an observational study that assessed the risk of major bleeds with concomitant use of selective serotonin reuptake inhibitors (SSRIs) and oral anticoagulants -  https://dtb.bmj.com/content/62/11/164. The main article discusses equity of care in the management of COPD and that those more at risk of COPD are also more likely to experience barriers to care - https://dtb.bmj.com/content/62/11/165. They begin by highlighting two articles* in the BMJ that consider the problem of conflicts of interest.   *Fabbri A, Grundy Q. Protecting early career physicians from commercial influence. BMJ. 2024 Sep 9;386:q1939. (https://www.bmj.com/content/386/bmj.q1939) McCartney M. Transparency as a means to conquer conflicts of interest is illusory. BMJ. 2024 Sep 24;386:q2092. (https://www.bmj.com/content/386/bmj.q2092)   Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.

In this podcast recorded in early July, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) continue to ignore political and sporting events and talk about the August issue of DTB. They discuss the editorial that highlights the growth in the use of psychotropic medication in children and young people and some of the challenges associated with this trend. They talk about a study that assessed the harms of changing frail older people with AF from warfarin to a DOAC. The main article is an overview of the evidence for fezolinetant for the treatment of menopausal vasomotor symptoms.

 

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.

In this podcast recorded in BMA House in December, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the January 2024 issue of DTB. They discuss continuity of care in general practice and the benefits it offers (https://dtb.bmj.com/content/62/1/2). They discuss a safety alert issued by the Medicines and Healthcare products Regulatory Agency that highlights a very small number of reports of new-onset or aggravation of pre-existing myasthenia gravis associated with statins (https://dtb.bmj.com/content/62/1/4). The main article is an overview of the management of acne (https://dtb.bmj.com/content/62/1/6). They begin the podcast by providing a brief update on the results of a trial that assessed the effect of semaglutide on cardiovascular outcomes in people aged ≥45 years with cardiovascular disease (but not diabetes) and a BMI ≥27 kg/m2 (plot spoiler: make sure you know your ARRs from your RRRs).

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email dtb@bmj.com. Thank you for listening.

In this podcast recorded in early April, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the May 2024 issue of DTB. They discuss the editorial that highlights the effect medicines have on greenhouse gas emissions and the need to consider the environmental impact of all aspects of the patient care pathway​ (https://dtb.bmj.com/content/62/5/66). They review the results of a study that assessed the effect of donanemab on early symptomatic Alzheimer's disease​ (https://dtb.bmj.com/content/62/5/67). The main article considers the evidence for cytisine, a nicotine receptor partial agonist, that has recently been licensed to facilitate quitting smoking​ (https://dtb.bmj.com/content/62/5/71). They begin by highlighting some useful resources relating to the safe use of valproate.   Other links: https://www.england.nhs.uk/patient-safety/sodium-valproate/  https://www.england.nhs.uk/publication/decision-support-tool-is-valproate-the-right-epilepsy-treatment-for-me/ https://www.gov.uk/government/collections/valproate-safety-measures https://www.gov.uk/guidance/valproate-use-by-women-and-girls   Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email dtb@bmj.com. Thank you for listening.  

In this podcast recorded in early December, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the January 2025 issue of DTB. They provide an overview of the editorial that questions whether it is time for the medicine Patient Information Leaflet (PIL) to include information on the impact of a medicine on clinical outcomes - https://dtb.bmj.com/content/63/1/2. They talk about a recent announcement from the Irish College of GPs that it is phasing out sponsorship from pharmaceutical companies as evidence suggests that ‘engagement between pharmaceutical companies and prescribers is associated with inappropriately increased prescribing rates, lower prescribing quality and increased prescription costs’ - https://dtb.bmj.com/content/63/1/3. The main article provides an overview of Ryeqo (relugolix, estradiol and norethisterone acetate) for the treatment of moderate to severe symptoms of uterine fibroids - https://dtb.bmj.com/content/63/1/6. The podcast ends with a farewell to James, who is stepping down as Editor-in-Chief after more than 12 years. James reflects on his time as a doctor, GP and Editor of DTB.   Other links: Is ASCOT all it's cracked up to be? https://www.bmj.com/content/331/7523/1023.1 Don't lose your head over ASCOT https://www.bmj.com/content/331/7523/1022.1

In this podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the Cancer Drug Fund for England; review a new indication for the combination of oxycodone and naloxone for the management of restless legs syndrome; and consider the impact of animal-derived medicines. Read the articles featured here: Editorial: NICE and the cancer drugs fund for England

Articles: 1. Targinact for restless legs syndrome 2. Implications of religious and cultural beliefs on selection of medicines

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) preview the December issue of DTB. This includes an editorial that discusses the results of a study that suggested that people who took antihypertensive medication at bedtime had a lower risk of a cardiovascular event. The editors talk about a threat to the supply of the Priadel brand of lithium carbonate. They also discuss the use of esketamine for treatment-resistant depression. This month's case report involves an unintentional overdose of hyoscine hydrobromide in a young child.

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening. Go well and stay well.

With the coronavirus pandemic restrictions still in place, this socially distanced DTB podcast features James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor), who provide an overview of the June issue of DTB. This includes an editorial that discusses whether clinicians should be deprescribing some medicines during the pandemic, and a summary of the EMA's advice on the use of drugs that affect the renin-angiotensin system in people who have COVID-19. The main article looks at the gastrointestinal risks of NSAIDs and the evidence for gastroprotection, and the issue finishes with a case report of drug reaction with eosinophilia and systemic symptoms syndrome in a patient taking lamotrigine. Please read the full issue: https://dtb.bmj.com/content/58/6.

Subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening. Go well and stay well.

In a series of podcasts to mark the 60th anniversary of DTB, we talk to some of DTB's Editorial Board members and other colleagues about their work and their involvement with DTB. In this podcast, David Phizackerley (DTB's deputy editor) talks to Dr Jo Congleton, who is a consultant in Integrated Respiratory Care in Brighton and Hove. She is also clinical lead for the Kent, Surrey, Sussex Academic Health and Science Network (AHSN) Respiratory Programme. Her interests are in chronic respiratory conditions (particularly COPD) and reducing both variation, and inequalities, in care. This special series of the DTB Podcast is produced by Leticia Amorim.

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In a series of podcasts to mark the 60th anniversary of DTB, we talk to some of DTB's Editorial Board members and other colleagues about their work and their involvement with DTB. In this podcast, recorded May 2022, David Phizackerley (DTB's deputy editor) talks to Joanna Girling who is a consultant in obstetric medicine in north London and has been involved with DTB since 2006. Joanna talks about her clinical work, her role with establishing the local maternity network and her involvement in research. She also talks about supporting women who have pre-existing medical conditions and who are pregnant or who are planning pregnancy and the importance of checking that they are on the most appropriate medicines. The contact address for the DTB team is dtb@bmj.com.

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listenin

In a series of podcasts to mark the 60th anniversary of DTB, we talk to some of DTB's Editorial Board members and other colleagues about their work and their involvement with DTB. In this podcast, David Phizackerley (DTB's deputy editor) talks to Dr John Dowden, the editor of Australian Prescriber since 1990. Australian Prescriber (https://www.nps.org.au/australian-prescriber) is an independent peer-reviewed journal providing critical commentary on drugs and therapeutics for health professionals, and like DTB, Australian Prescriber was a founder member of the International Society of Drug Bulletins. At the time of recording, John highlighted that public funding for NPS Medicinewise (https://www.nps.org.au/), the organisation that publishes Australian Prescriber, was under threat and unfortunately the Australian Government withdrew funding and the organisation closed at the end of December. John and his team were made redundant, and the future of Australian Prescriber is uncertain. We wrote an editorial that criticises the decision to remove funding from NPS Medicinewise and you can find this in the January 2023 issue of DTB (https://dtb.bmj.com/content/61/1/2). This special series of the DTB Podcast is produced by Letícia Amorim and edited by Brian O'Toole.

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss a national initiative to identify and manage people at high risk of developing type 2 diabetes. Full article available here: http://dtb.bmj.com/content/55/4/37. The editors also review the evidence for an HRT product containing bazedoxifene and conjugated oestrogens (http://dtb.bmj.com/content/55/4/42) and discuss a new formulation of lidocaine and prilocaine licensed for treatment of premature ejaculation (http://dtb.bmj.com/content/55/4/45). The highlights of the DTB April 2017's issue here:

http://dtb.bmj.com/content/55/4/38.

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss a national campaign in England that is tackling the inappropriate use of antipsychotic and antidepressant medicines in people with learning or intellectual disability. Read the article: http://dtb.bmj.com/content/56/4/37.

The editors also review the evidence for a once-daily triple inhaler for maintenance treatment for adults with moderate to severe COPD (http://dtb.bmj.com/content/56/4/42), and discuss off-label use of high-dose antihistamines for chronic spontaneous urticaria in adults (http://dtb.bmj.com/content/56/4/45).

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) review the April issue of DTB. The editorial discusses variability in the management of people with severe asthma (https://dtb.bmj.com/content/59/4/50). The editors talk about a summary of an article on changes in prescribing of statins (https://dtb.bmj.com/content/59/4/53). The main article explores the use of aspirin for pre-eclampsia (https://dtb.bmj.com/content/59/4/56) and the case report is of a patient who developed omeprazole-induced hypomagnesaemia (https://dtb.bmj.com/content/59/4/60).

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the April 2022 issue of DTB. They talk about DTB's 60th anniversary, the importance of independent scrutiny of new medicines and the need to question how medicines are licensed and used (https://dtb.bmj.com/content/60/4/50). They highlight the benefits of a comprehensive national register of conflicts of interest and discuss a study that compared a quadpill containing low doses of four antihypertensive agents with a standard dose of irbesartan (https://dtb.bmj.com/content/60/4/56). They also review a study that assessed clinicians' awareness of the harms from long-term use of nitrofurantoin (https://dtb.bmj.com/content/60/4/59) and provide an overview of an article on managing hypertension in pregnancy (https://dtb.bmj.com/content/60/4/60). The editors also look back at the very first issue of DTB that was published on 20th April 1962 (https://dtb.bmj.com/content/s1-1/1).

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the April 2023 issue of DTB. They discuss evidence around morning and evening doses of antihypertensive medication (https://dtb.bmj.com/content/61/4/50). They review a study that analysed health technology assessment decisions made in Australia, Canada and England (https://dtb.bmj.com/content/61/4/51) and also talk about managing skin conditions in women who are planning pregnancy or who are pregnant (https://dtb.bmj.com/content/61/4/55). They begin by responding to a listener's letter about last month's podcast.

The Prescribing for pregnancy series of articles can be found here: https://dtb.bmj.com/pages/prescribing-for-pregnancy-series/

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the presentation of guidelines and ways of making them more accessible. Read the full editorial here: http://dtb.bmj.com/content/54/8/85.full There’s also an evaluation of the use of capsaicin for diabetic peripheral neuropathy. Article accessible here: http://dtb.bmj.com/content/54/8/90.full

The DTB editors also talk about medicines, excipients and dietary intolerances. Article accessible here: http://dtb.bmj.com/content/54/8/93.full

In the August's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the results of an awarding research paper that assessed the impact of spending the second stage of labour either in a recumbent or upright position. Read the editorial: https://dtb.bmj.com/content/56/8/85.

The editors also consider nutritional support in primary care (https://dtb.bmj.com/content/56/8/90) and discuss new licensing pathways that provide faster access to medicines (https://dtb.bmj.com/content/56/8/93).

In August's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss pre-eclampsia and the benefit of measuring the level of placental growth factor to help speed up diagnosis. The editors also talk about the challenge of communicating evidence to patients and review a case of complex encephalopathy arising from the combination of opioids and gabapentin.

Read the full issue: https://dtb.bmj.com/content/57/8.

Another socially distanced DTB podcast features James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) who provide an overview of the August issue of DTB. This includes an editorial discussing the changes that have taken place in general practices and the new ways of working that have been developed during the coronavirus pandemic (https://dtb.bmj.com/content/58/8/114). The main article reviews the evidence for using vitamin D and calcium in older people who have osteoporosis (https://dtb.bmj.com/content/58/8/122) and the case report highlights the problems faced by a young man who developed a hyperkinetic reaction to dihydrocodeine (https://dtb.bmj.com/content/58/8/126). Read the full issue: https://dtb.bmj.com/content/58/8.

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening. Go well and stay well.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the August issue of DTB (https://dtb.bmj.com/content/59/8). The editors talk about the MHRA's decision to reverse the EMA's decision and allow boron-containing chloramphenicol eye drops to be used in children aged below 2 years. They discuss a scheme in England that allows hospital staff to refer patients who would benefit from extra guidance around their medicines regimen for support from a community pharmacy (https://dtb.bmj.com/content/59/8/114). They also highlight the risk from concurrent opioid and benzodiazepine use (https://dtb.bmj.com/content/59/8/116), and talk about home blood pressure monitoring (https://dtb.bmj.com/content/59/8/119).

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the August 2022 issue of DTB. They discuss progress in reducing use of psychotropic medications in adults and children with a learning disability, autism or both (https://dtb.bmj.com/content/60/8/114). They also provide an overview of a study that assessed the effect of deprescribing antihypertensive medication in older people (https://dtb.bmj.com/content/60/8/118) and talk about a national safety alert relating to amiodarone (https://dtb.bmj.com/content/60/8/116). They end the podcast with a discussion on the evidence for the lipid-lowering drug bempedoic acid and its effect on reducing low-density lipoprotein-cholesterol and the lack of evidence on clinical outcomes (https://dtb.bmj.com/content/60/8/120). The contact address for the DTB team is dtb@bmj.com.

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

"Clarity begins at home". In this podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) start by remembering DTB's founding editor, Andrew Herxheimer's golden rules for prescribing. The DTB editors also discuss 'gliptins' in the management of diabetes and evidence from recent cardiovascular outcome studies, as well as, psychological interventions for eating disorders.

The full editorial is available here: http://dtb.bmj.com/content/early/2016/12/05/dtb.2016.12.0439.full. You can also watch the video interview with Andrew Herxheimer here: http://tinyurl.com/jybvocp.

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the challenge of prescribing specialist drugs in primary care and highlight problems associated with the use of shared care protocols. http://dtb.bmj.com/content/55/12/133

The editors also review the evidence for an inhaler containing beclometasone, formoterol and glycopyrronium that has recently been licensed for the management of COPD - http://dtb.bmj.com/content/55/12/138 - and discuss the use of dimethyl fumarate for psoriasis. http://dtb.bmj.com/content/55/12/141

In December's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the conditional authorisation process for medicines and the need for clearer labelling of medicines that have been through this approval processes. The editors also consider common sources of information on medicines for patients and review a case of interstitial lung disease associated with adalimumab.

Read the issue: https://dtb.bmj.com/content/56/12.

In December's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) consider the results of a recent study that assessed the effect of a combination pill containing aspirin, atorvastatin, enalapril and hydrochlorothiazide on major cardiovascular outcomes - https://dtb.bmj.com/content/57/12/178. The editors discuss prasterone, a newly introduced treatment for vulvar and vaginal atrophy - https://dtb.bmj.com/content/57/12/185. They also review a case report of retrograde ejaculation associated with quetiapine and treatment with low-dose imipramine - https://dtb.bmj.com/content/57/12/189.

Read the December issue on the DTB website: https://dtb.bmj.com/content/57/12.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the December issue of DTB. They discuss a recently published national report on overprescribing of medicines. The editors talk about a study that assessed the accuracy of home blood pressure monitors (https://dtb.bmj.com/content/59/12/179) and highlight a safety alert on topical steroid withdrawal reactions (https://dtb.bmj.com/content/59/12/184). They also review an article on the US Food and Drug Administration's decision to license bremelanotide and flibanserin for 'hypoactive sexual desire disorder’ in women (https://dtb.bmj.com/content/59/12/185).

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the December 2022 issue of DTB. They discuss cognitive changes that have been reported during the menopause and whether there is a role for MHT (https://dtb.bmj.com/content/60/12/178). They highlight an observational study that found an association between the use of sodium-containing paracetamol and cardiovascular events (https://dtb.bmj.com/content/60/12/181), and talk about the evidence for increasing the dose of vedolizumab in IBD (https://dtb.bmj.com/content/60/12/183). They begin the podcast by talking about their top three highlights from 2022. The contact address for the DTB team is dtb@bmj.com.

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the importance of developing patient decision aids to support the implementation of clinical guidelines (http://dtb.bmj.com/content/56/2/13).

The editors also review the evidence for cladribine for the treatment of highly active relapsing multiple sclerosis (http://dtb.bmj.com/content/56/2/21) and discuss the latest levonorgestrel IUS device to be marketed for contraception (http://dtb.bmj.com/content/56/2/18).

In February's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the use of inhaled corticosteroids in the management of COPD (https://dtb.bmj.com/content/57/2/18). The editors also consider subclinical hypothyroidism in pregnancy (https://dtb.bmj.com/content/57/2/22) and discuss Gilbert’s syndrome (https://dtb.bmj.com/content/57/2/27).

Read the full issue: https://dtb.bmj.com/content/57/2

In February's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) consider the impact of conflicts of interest and highlight the need to establish comprehensive registers of conflicts of interest for healthcare professionals, healthcare providers and patient support groups. They briefly review an article on melatonin for jet lag (a longer version is available here: https://soundcloud.com/bmjpodcasts/melatonin-for-jet-lag?in=bmjpodcasts/sets/dtb-podcast), discuss a review of the management of nocturnal enuresis and highlight a report of a possible case of statin-induced delayed rhabdomyolysis. Read the full February issue: https://dtb.bmj.com/content/58/2

If you enjoy the podcast, please subscribe to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment at https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309. Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) discuss the February issue of DTB. This includes an editorial that highlights the benefits associated with the human papillomavirus (HPV) and herpes zoster vaccination programmes (https://dtb.bmj.com/content/early/2021/01/11/dtb.2020.000048). The editors talk about a cohort study, which found that many older people who had recently been prescribed a calcium-channel blocker for hypertension were subsequently given a loop diuretic. The main article reviews the use of prescribing safety indicators to improve outcomes for patients and the case report is of a patient who developed immune checkpoint inhibitor-mediated large vessel vasculitis. Read the issue on the DTB website: https://dtb.bmj.com/content/59/2

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the February 2022 issue of DTB. They talk about some of the details from a national report on overprescribing and discuss its implications (https://dtb.bmj.com/content/60/2/18). The editors review a study that highlighted overprescribing of short-acting beta agonists in people with asthma (https://dtb.bmj.com/content/60/2/21). They also discuss an article on prescribing for women of childbearing age who have inflammatory bowel disease and managing medicines during pregnancy (https://dtb.bmj.com/content/60/2/24).

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the February 2023 issue of DTB. They discuss concerns over a national initiative in England to transfer people with atrial fibrillation to edoxaban from other DOACs (https://dtb.bmj.com/content/61/2/18). They review a study that examined whether the correct dose of DOAC was used in people with renal impairment (https://dtb.bmj.com/content/61/2/21). They talk about the use of empagliflozin in people with heart failure (https://dtb.bmj.com/content/61/2/22) and finish with an overview of an article that discusses prescribing for pregnancy for those with inflammatory rheumatic disease (https://dtb.bmj.com/content/61/2/24). 60th anniversary interview with Dr John Dowden: https://soundcloud.com/bmjpodcasts/dtb-60th-anniversary-podcast-interview-john-dowden Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014–2019): https://heart.bmj.com/content/109/3/195 The contact address for the DTB team is dtb@bmj.com.

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the risk of hyperkalaemia associated with spironolactone in people with heart failure. They consider recent advice issued by the Medicines and Healthcare products Regulatory Agency and highlight the importance of regular monitoring of potassium and renal function.

The editors also review the evidence for daclizumab, a drug for relapsing multiple sclerosis, and provide a brief introduction to the rationale and methods of qualitative research in health care.

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss a proposal from NHS England to introduce a sore throat test-and-treat service in community pharmacies. They review the evidence on the management of sore throat and examine the assumptions that underpin the proposed service. The editors also discuss pitolisant, a new drug for narcolepsy, and review the evidence for LAMA/LABA inhaler combinations for people with COPD.

Read more about this issue here: http://dtb.bmj.com/content/55/1.toc.

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the importance of exercise, diet and behaviour modification in the management of obesity and consider the limitations of anti-obesity drugs. http://dtb.bmj.com/content/56/1/1

The editors also review the evidence for ▼patiromer, a cation exchange polymer, that has recently been marketed for the management of hyperkalaemia - http://dtb.bmj.com/content/56/1/6 and discuss the management of gout. http://dtb.bmj.com/content/56/1/9

In January's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) consider the burden of overprescribing and discuss how to tackle some of the barriers to deprescribing (https://dtb.bmj.com/content/58/1/2). They also review an article on the place of aspirin for primary prevention of cardiovascular disease (https://dtb.bmj.com/content/58/1/3), highlight an article on prescribing for pregnancy for women with mental health issues (https://dtb.bmj.com/content/58/1/8), and discuss a case report of sitagliptin-induced seronegative rheumatoid arthritis (https://dtb.bmj.com/content/58/1/12).

Please subscribe to get episodes automatically downloaded to your phone and computer every month. If you enjoy the podcast, please leave us a review or a comment at https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309. Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the January 2022 issue of DTB. They discuss the UK Medicines and Healthcare products Regulatory Agency's decision to license the oral antiviral drug molnupiravir (Lagevrio) and the paucity of publicly available clinical trial data - https://dtb.bmj.com/content/60/1/2. The editors talk about a study that highlighted potentially inappropriate prescribing in middle-aged adults - https://dtb.bmj.com/content/60/1/6. They also review an article on some of the challenges facing people when they try to stop taking antidepressants - https://dtb.bmj.com/content/60/1/7.

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the January 2023 issue of DTB. They begin with another reminder of the concerns over the use of sodium valproate. They talk about the closure of NPS MedicineWise in Australia and the uncertainty over the future of Australian Prescriber - https://dtb.bmj.com/content/61/1/2. They highlight the risk of eye problems with dupilumab - https://dtb.bmj.com/content/61/1/6 (see more links below) and the challenge of making sure that primary care clinical systems record drugs prescribed by specialists. They discuss toxocarosis in humans and the risk of environmental contamination from parasiticides used for deworming cats and dogs (https://dtb.bmj.com/content/61/1/3 and https://dtb.bmj.com/content/61/1/7). Dupilumab links: 1. Reji MA, Haque A, Goyal S, et al. Dupilumab-induced ocular surface disease: a primer. BMJ Case Reports CP 2022;15:e249019. https://casereports.bmj.com/content/15/4/e249019 2. Nahum Y, Mimouni M, Livny E, et al. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. British Journal of Ophthalmology 2020;104:776-9. https://bjo.bmj.com/content/104/6/776 The contact address for the DTB team is dtb@bmj.com.

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

Welcome to the DTB podcast, which is recorded monthly to coincide with the release of the print issue of DTB. James Cave (DTB Editor in Chief) and David Phizackerley (DTB Deputy Editor) discuss the contents of the July 2015 issue of DTB.

Read all the articles featured here: http://dtb.bmj.com/content/53/7.toc

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the role of Electroconvulsive Therapy (ECT) in the management of psychiatric disorders. Article here: http://dtb.bmj.com/content/55/7/1.

The editors also discuss the use of liraglutide for obesity (related article here: http://dtb.bmj.com/content/55/7/78)and highlight some of the challenges associated with the management of people with clinical features of both asthma and COPD (http://dtb.bmj.com/content/55/7/66).

In July's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the work that patients have to do to manage their health and how this is not recognised by clinical guidelines. The editors also talk about the non-drug management of low back pain and discuss a case of metformin-associated lactic acidosis precipitated by liraglutide use.

Read the full issue: dtb.bmj.com/content/57/7.

Another socially distanced DTB podcast features James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor), who provide an overview of the July issue of DTB. This includes an editorial that discusses some of the challenges in supplying low-dose aspirin to pregnant women for prevention of pre-eclampsia, a DTB Forum article by Margaret McCartney on some of the challenges to evidence-based medicine during the coronavirus pandemic and a DTB Select update on the safety of ibuprofen in people with COVID-19. The main article discusses managing antiepileptic drugs before and during pregnancy for women with epilepsy, and this month's case report is of amiodarone-induced diffuse alveolar haemorrhage. Read the full issue: https://dtb.bmj.com/content/58/7

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening. Go well and stay well.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the July issue of DTB. The editors catch up on developments with proposals for all doctors in the UK to provide financial and non-financial declarations of interest. They discuss the problem of boron in chloramphenicol eye drop products and the impact on treating children aged under 2 years (https://dtb.bmj.com/content/59/7/98). The editors also talk about PPIs for persistent throat symptoms (https://dtb.bmj.com/content/59/7/102), the dose of folic acid for use with methotrexate (https://dtb.bmj.com/content/59/7/103) and a case of a patient who developed severe hypophosphataemia with an oral bisphosphonate (https://dtb.bmj.com/content/59/7/107).

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the July 2022 issue of DTB. They discuss the proposed reclassification of estradiol vaginal tablets from Prescription Only Medicine to a Pharmacy medicine (https://dtb.bmj.com/content/60/7/98) and review a study that assessed pharmaceutical industry funding of All Party Parliamentary Groups (https://dtb.bmj.com/content/60/7/100). They talk about the evidence for the lipid-lowering drug inclisiran and its effect on reducing low-density lipoprotein-cholesterol and the lack of evidence on clinical outcomes (https://dtb.bmj.com/content/60/7/102). The editors also highlight a case report of acute lung toxicity caused by nitrofurantoin (https://dtb.bmj.com/content/60/7/108).

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In the June’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss whether a recently published large meta-analysis on the effectiveness of antidepressants tells us anything new. Read the editorial here: dtb.bmj.com/content/56/6/61.

The editors also review the evidence for the combination analgesic of tramadol/dexketoprofen (dtb.bmj.com/content/56/6/66), and question the dose of paracetamol for older people (dtb.bmj.com/content/56/6/69).

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) review the June issue of DTB. The list of articles mentioned in this podcast: The Editorial “COVID-19 vaccination in pregnancy” - https://dtb.bmj.com/content/59/6/82 DTB select “Stepping down asthma treatment” - https://dtb.bmj.com/content/59/6/85 Review “Prescribing for pregnancy: managing diabetes” - https://dtb.bmj.com/content/59/6/88 Republished case report “Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin)” - https://dtb.bmj.com/content/59/6/93

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the June 2022 issue of DTB. They discuss the impact that the cessation of spirometry services in primary care has had on diagnosing obstructive lung disease (https://dtb.bmj.com/content/60/6/82). They highlight two separate patient safety incident reports from the Healthcare Safety Investigation Branch - confusion over the prescribed dose of oral morphine solution and the harm caused by a standard therapeutic dose of paracetamol in a frail older person (https://dtb.bmj.com/content/60/6/84). The editors also talk about an article on serotonin syndrome (https://dtb.bmj.com/content/60/6/88). Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

Read the June issue: https://dtb.bmj.com/content/60/6

Welcome to the DTB podcast, which is recorded monthly to coincide with the release of the print issue of DTB.

James Cave (DTB Editor in Chief) and David Phizackerley (DTB Deputy Editor) discuss the contents of the June 2015 issue of DTB.

Read all the articles featured here: http://dtb.bmj.com/content/53/6.toc

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss some of the implications related to funding of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV). They consider the Court of Appeal decision on funding and the role of clinical and health economic evaluations for preventative treatments. Full article available here: http://dtb.bmj.com/content/55/3/25. The editors also review the evidence for a new formulation of desmopressin for nocturia in adults (http://dtb.bmj.com/content/55/3/30) and discuss penicillin allergy (http://dtb.bmj.com/content/55/3/33). Find out more about the March issue here:

http://dtb.bmj.com/content/55/3/26.

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss some of the difficulties in implementing clinical guidelines for the management of elevated blood pressure and the potential impact of changes in the threshold for a diagnosis of hypertension (http://dtb.bmj.com/content/56/3/25). The editors also review the evidence for dupliumab for the treatment of moderate-to-severe atopic dermatitis in adults (http://dtb.bmj.com/content/56/3/30) and discuss drug names (http://dtb.bmj.com/content/56/3/33).

Read the full March 2018 issue here: http://dtb.bmj.com/content/56/3.

In March's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the decision to extend the license for dapagliflozin 5 mg tablets to include use by people with type 1 diabetes and highlight concerns over the incidence of diabetic ketoacidosis. They review an article on managing asthma before and during pregnancy and talk about a case of partial nephrogenic diabetes insipidus associated with lithium therapy. Read the full March issue: dtb.bmj.com/content/58/3

If you enjoy the podcast, please subscribe to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment at https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309. Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) review the March issue of DTB (https://dtb.bmj.com/content/59/3). The editorial discusses a national safety alert that highlighted the risk of dependence associated with prolonged use of opioids for non-cancer pain and a proposal that all opioid medicines in the UK carry the warning "can cause addiction" (https://dtb.bmj.com/content/59/3/34). The editors talk about an article on the rationale and science behind bisphosphonate holidays (https://dtb.bmj.com/content/59/3/35). The main article explores the risk of nitrosamine contamination in medicines (https://dtb.bmj.com/content/59/3/39) and the case report is of a patient who developed an unusually impressive atorvastatin-induced elevation of serum alkaline phosphatase (https://dtb.bmj.com/content/59/3/43). Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

Also, DTB is running a short survey to find out what people think of our content. Please visit https://dtb.bmj.com to find a link to the survey.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the March 2022 issue of DTB. They talk about paracetamol and its effect on blood pressure and discuss progress on moving to inhalers that have less of an impact on the environment (https://dtb.bmj.com/content/60/3/34). The editors review a study that examined harms from medicines (https://dtb.bmj.com/content/60/3/37) and discuss the use of naldemedine in the management of opioid-induced constipation (https://dtb.bmj.com/content/60/3/39).

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the March 2023 issue of DTB. They discuss incorrect penicillin allergy labels and ways that these can be corrected (https://dtb.bmj.com/content/61/3/34). They review clinical trial results for lecanameb in early Alzheimer's disease (https://dtb.bmj.com/content/61/3/37) and also talk about a new combined oral contraceptive that contains estetrol and drospirenone (https://dtb.bmj.com/content/61/3/39). They begin by discussing a proposal from the National Institute for Health and Care Excellence to lower the threshold for offering statins for primary prevention. The contact address for the DTB team is dtb@bmj.com.

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In this podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss testosterone replacement therapy; review the new antidepressant vortioxetine; and consider the impact of drugs on the QT interval. The DTB podcast is recorded monthly to coincide with the release of the print issue of DTB.

Read all the articles featured here: dtb.bmj.com/content/54/3.toc

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the evidence for pulmonary rehabilitation for COPD and highlight the need for more publicity for its benefits. Read the editorial here: http://dtb.bmj.com/content/56/5/49.

The editors also review the evidence for safinamide for Parkinson’s disease (http://dtb.bmj.com/content/56/5/54), and discuss the use of bezlotoxumab, a monoclonal antibody licensed for the prevention of recurrence of Clostridium difficile infection in adults who are at high risk of recurrence (http://dtb.bmj.com/content/56/5/57).

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) review the May issue of DTB. In light of the "First do no harm" report, the editorial discusses the need for a mandatory register of payments made by pharmaceutical and medical device companies to healthcare professionals, healthcare organisations and patient support organisations (https://dtb.bmj.com/content/59/5/66). The editors talk about the BTS guideline on long-term use of macrolides (https://dtb.bmj.com/content/59/5/67). The main article explores the use of CAR T-cell therapy (https://dtb.bmj.com/content/59/5/73) and the case report is of a patient who developed quinidine hypersensitivity (https://dtb.bmj.com/content/59/5/77).

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the May 2022 issue of DTB. They talk about drug bulletins across the world and the role of the International Society of Drug Bulletins in supporting bulletins and ensuring that they are intellectually and financially independent (https://dtb.bmj.com/content/60/5/66). They review a study that assessed the use of mirtazapine for treating agitation in people with dementia (https://dtb.bmj.com/content/60/5/68). The editors also discuss the evidence behind two new oral antivirals that have been licensed for the treatment of covid-19 (https://dtb.bmj.com/content/60/5/73).

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the May 2023 issue of DTB. They celebrate 60 years since DTB became independent from The Medical Letter and discuss what DTB stands for (https://dtb.bmj.com/content/61/5/66). They review a retrospective cohort study involving people taking oral anticoagulants that compared the risk of bleeding and embolic events in new users of NSAIDs with those not prescribed NSAIDs (https://dtb.bmj.com/content/61/5/67). They also talk about the main review article that explores the therapeutics of siRNA medicines (https://dtb.bmj.com/content/61/5/72). They begin by discussing the UK Government’s recent Budget statement that the MHRA will introduce a new approval process for medicines that have been licensed elsewhere.

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss changes to the rubella screening programme and the need to ensure that MMR vaccinations are up to date, especially in younger women born outside the UK. Read the full editorial here: http://dtb.bmj.com/content/54/11/121.full.

The editors also discuss prescribing information sources (http://dtb.bmj.com/content/54/11/129.full) and the evidence on the management of difficult to treat severe asthma (http://dtb.bmj.com/content/54/11/126.full).

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the challenges associated with prescribing for long-term conditions in women who are pregnant and raise concerns that medicines may be stopped inappropriately. Read the editorial here: http://dtb.bmj.com/content/55/11/121. The editors also review a combination product containing naltrexone and bupropion that is licensed for the management of obesity - http://dtb.bmj.com/content/55/11/126 - and discuss bleeding risks associated with direct oral anticoagulants (DOACs)- http://dtb.bmj.com/content/55/11/129.

http://dtb.bmj.com/

In November's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss whether primary care targets for managing blood pressure control in older people are achievable or desirable. The editors also introduce the first of a series of articles that consider therapeutic challenges when preparing for pregnancy and highlight some of the key issues that should be considered for all women as part of pre-pregnancy care. They also review a case report of apixaban-induced acute interstitial nephritis.

Read the full November issue: https://dtb.bmj.com/content/57/11

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) preview the November issue of DTB. This includes an editorial that focuses on the National Institute of Health and Care Excellence's draft guideline on the management of chronic pain, and in particular, the approach to treating chronic primary pain (https://dtb.bmj.com/content/58/11/162). The editors talk about a new patient-held steroid emergency card that has been introduced to help healthcare staff identify adult patients with adrenal insufficiency (https://dtb.bmj.com/content/58/11/163). They also discuss the diagnosis and treatment of orthostatic hypotension. This month's case report involves a patient who developed medication-related osteonecrosis (MRONJ) of the mandible and maxilla (https://dtb.bmj.com/content/58/11/172).

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening. Go well and stay well.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the November issue of DTB. They discuss a French initiative that identifies a range of drugs that should not be prescribed (https://dtb.bmj.com/content/59/11/162) and talk about the difficulty of assessing whether patients' penicillin allergy records are correct (https://dtb.bmj.com/content/59/11/163). They also review an article on the use of romosozumab for osteoporosis (https://dtb.bmj.com/content/59/11/169). They begin by highlighting DTB's blog for World Evidence-Based Healthcare Day (https://worldebhcday.org/) on the role of independent drug bulletins during an info-demic.

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the November 2022 issue of DTB. They discuss the use of faecal microbiota transplantation to treat gastrointestinal infections and in particular its role in managing Clostridioides difficile infection (https://dtb.bmj.com/content/60/11/162). They highlight a study that assessed the effect of interrupting methotrexate treatment on COVID-19 booster vaccine response (https://dtb.bmj.com/content/60/11/163) and review a new drug that is licensed for treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy (https://dtb.bmj.com/content/60/11/166). The podcast begins with the editors talking about the response to October's editorial "Stop advertising".

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In October's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss wide variation in the use of fibrates and the need for clinicians to consider whether their prescribing of fibrates is up to date and appropriate for their patients. The editors also talk about the evidence for fibrates in primary and secondary prevention of cardiovascular disease, highlight recent changes in the BNF and review a case of severe acute ocular hypertension following pulsed methylprednisolone.

Read the full October issue: https://dtb.bmj.com/content/57/10

A socially distanced podcast with James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) previewing the October issue of DTB. This includes an editorial that discusses the harms caused by medicines and medical devices and highlights concerns over proposals to speed up the UK licensing process for medicines. The editors talk about an article that looks at the influence of pharmaceutical marketing. They also review three new medicines used to prevent migraines. This month's case report involves a patient with rheumatoid arthritis who received latent tuberculosis infection treatment prior to treatment with a biologic agent, and developed shock with resistant hypotension on re-exposure to rifampicin. Read the full issue: https://dtb.bmj.com/content/58/10

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening. Go well and stay well.

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the October 2022 issue of DTB. They discuss whether the language used in announcements from organisations such as NHS England, NICE and the MHRA regarding new medicines is appropriate and highlight concerns that some press releases are at risk of promoting POMs to the public (https://dtb.bmj.com/content/60/10/146). They review a study that assessed the effect that regular doses of paracetamol had on blood pressure (https://dtb.bmj.com/content/60/10/147) and talk about an article that discusses the role played over the past 20 years by groups, organisations and individuals that have been critical of the pharmaceutical industry (https://dtb.bmj.com/content/60/10/151).

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the fragmented approach to communicating additional risk minimisation measures for medicines. Article available here: http://dtb.bmj.com/content/55/10/1.

The editors also review the long-term safety of PPIs (http://dtb.bmj.com/content/55/10/117) and discuss the use of the live attenuated influenza vaccine for children (http://dtb.bmj.com/content/55/10/114).

Why should we worry about the new European Medicines Agency (EMA) pilot project to accelerate the approval of new drugs? James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the October issue Editorial, that looks at the pros and cons of this new trend both in the USA and Europe. Read the full article here: http://dtb.bmj.com/content/54/10/109.full. Also in this podcast: • the use of the new antibiotic Fosfomycin trometamol for the treatment of acute uncomplicated lower urinary tract infections (UTIs) –http://dtb.bmj.com/content/54/10/114.abstract;

• as well as the "health condition" of point-of-care tests for respiratory tract infections (RTI) in improving diagnosis capabilities in GP surgeries - http://dtb.bmj.com/content/54/10/117.full.

In April's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) highlight some of the challenges of prescribing direct acting oral anticoagulant (DOAC) drugs for people with renal impairment. The editors also talk about the use of saline nasal irrigation and discuss central sensitisation syndrome.

Read the issue online: https://dtb.bmj.com/content/57/4.

In April's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss lung volume reduction surgery for patients with emphysema-predominant COPD (https://dtb.bmj.com/content/58/4/50). They highlight the results of a trial of low-dose amitriptyline for chronic low back pain (https://dtb.bmj.com/content/58/4/53), discuss the use of depot triamcinolone injection for hay fever (https://dtb.bmj.com/content/58/4/57), and talk about a case in which dapagliflozin was thought to have caused euglycaemic diabetic ketoacidosis (https://dtb.bmj.com/content/58/4/60). If you enjoy the DTB podcast, please subscribe to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

Read the full April issue: dtb.bmj.com/content/58/4

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the supply of medicines from online primary care services (article here: http://dtb.bmj.com/content/55/8/85).

The editors also review two recently licensed drugs: eluxadoline, a mixed opioid receptor agonist/antagonist for irritable bowel syndrome (http://dtb.bmj.com/content/55/8/90) and an oral formulation of glycopyrronium (http://dtb.bmj.com/content/55/8/93) for severe drooling in children.

In this podcast James Cave (Editor in Chief) and David Phizackerley (Deputy Editor) discuss some of the challenges associated with the national COVID-19 vaccination programme. In particular, they highlight the importance of making information on the vaccines’ safety and efficacy available to help people make an informed decision on vaccination. Read the paper: https://dtb.bmj.com/content/early/2020/11/24/dtb.2020.000071

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening. Go well and stay well.

In this podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss stopping rules for medicines used to manage long-term conditions; naloxegol for the management of opioid-induced constipation that has failed to respond to laxative therapy; and the plethora of new drugs and preparations for the management of open-angle glaucoma in adults. The DTB podcast is recorded monthly to coincide with the release of the print issue of DTB.

Read all the articles featured here: http://dtb.bmj.com/content/53/12.toc

In January's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss whether intravenous antibiotics are always needed. The editors also consider the challenge of stopping antipsychotic drug treatment in people with intellectual disability and review a case of angioedema of the small bowel caused by lisinopril.

Read the issue: dtb.bmj.com/content/57/1.

In July’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the risk of drug interactions with herbal medicines. Read the editorial: https://dtb.bmj.com/content/56/7/73.

The editors also review the evidence for ocrelizumab for relapsing MS and early primary progressive MS (https://dtb.bmj.com/content/56/7/80), and discuss the role of metformin in people with type 1 diabetes (https://dtb.bmj.com/content/56/7/78).

In this month’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the use of high-dose inhaled corticosteroids in asthma and COPD. The editors also highlight some of the challenges associated with the management of superficial venous thrombosis of the leg and discuss the use of carbohydrate deficient transferrin as a biomarker for the assessment of chronic alcohol use. Read more about the DTB's June 2017 issue: http://dtb.bmj.com/content/55/6#DTBSelect. Editorial: http://dtb.bmj.com/content/55/6/61.

Related articles: http://dtb.bmj.com/content/55/6/66 and http://dtb.bmj.com/content/55/6/69.

In June's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) consider the European Medicines Agency's decision to amend the licence for omega-3 fatty acid medicines so that they will no longer be authorised for secondary prevention after myocardial infarction. The editors also review ospemifene, a new medicine for the management of vulvar and vaginal atrophy and discuss a case of delusional infestation in the treatment of ADHD with atomoxetine.

Read the full issue: https://dtb.bmj.com/content/57/6.